Clinical trials demonstrate safety and efficacy with EPA (1.6 g) + DHA (0.8 g) daily for 12 weeks in lung cancer patients, showing improved nutritional status and suppressed inflammatory markers (CRP, TNF-α, IL-6) (63). The gene discussed is IL6; the disease is lung carcinoma.